Off-label use of tofacitinib: a potential treatment option for SAPHO syndrome

被引：9
|
作者：
Xie, Wenhui [1 ]
Huang, Hong [1 ]
Zhang, Zhuoli [1 ]
机构：
[1] Peking Univ First Hosp, Dept Rheumatol & Clin Immunol, Beijing 100034, Peoples R China
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷 / 06期
关键词：
D O I：
10.1136/annrheumdis-2020-217854
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Response to: 'Off-label use of tofacitinib: a potential treatment option for SAPHO syndrome' by Xie et al
    Li, Yueting
    Cao, Yihan
    Li, Chen
    Zhang, Wen
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (06)
  • [2] Off-label Use of Secukinumab: A Potential Therapeutic Option for SAPHO Syndrome
    Wang, Gang
    Zhuo, Ning
    Li, Jingyang
    JOURNAL OF RHEUMATOLOGY, 2022, 49 (06) : 656 - 656
  • [3] Off-label Use of Secukinumab: A Potential Therapeutic Option for SAPHO Syndrome reply
    Li, Chen
    Geng, Shaohui
    Wei, Shufeng
    Guo, Shuwen
    JOURNAL OF RHEUMATOLOGY, 2022, 49 (06) : 657 - 657
  • [4] Tofacitinib: a successful treatment option for SAPHO syndrome
    Sarikaya Solak, Sezgi
    Yelgen Ilyas, Hande
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2024, 63 (05) : 671 - 674
  • [5] Tofacitinib/UpadacitinibRash, anaphylaxis and myelosuppression and off-label use
    Reactions Weekly, 2024, 2016 (1) : 465 - 465
  • [6] Off-label Use of Mepolizumab: A Potential Therapeutic Option for Eosinophilic Cystitis
    Wang, G.
    Zhuo, N.
    Liu, Z.
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2024, 34 (04)
  • [7] RituximabToxoinfectious syndrome and off-label use
    Reactions Weekly, 2023, 1986 (1) : 388 - 388
  • [8] Off-label drug use in the treatment of polycystic ovary syndrome
    Vitek, Wendy
    Alur, Snigdha
    Hoeger, Kathleen M.
    FERTILITY AND STERILITY, 2015, 103 (03) : 605 - 611
  • [9] Off-label studies on tofacitinib in dermatology: a review
    Tegtmeyer, Kyle
    Zhao, Jeffrey
    Maloney, Nolan J.
    Atassi, Giancarlo
    Beestrum, Molly
    Lio, Peter A.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2021, 32 (04) : 399 - 409
  • [10] BlinatumomabNeurotoxicity syndrome following off-label use
    Reactions Weekly, 2024, 1998 (1) : 121 - 121
12345